Navigation Links
Micell Technologies Announces Presentation of Clinical Data at TCT 2011

DURHAM, N.C., Nov. 2, 2011 /PRNewswire/ -- Micell Technologies, Inc. today announced that it has completed a preliminary analysis of data from the first-in-human clinical study, DESSOLVE I, of the MiStent® Sirolimus Drug Eluting Coronary Stent System, a thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation that is designed for controlled drug release. Four, six and eight month data will be presented at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2011) in San Francisco, CA.

The presentation will be given in a Scientific Session, "Next Generation Drug-Eluting Stents and Bioabsorbable Scaffolds: Session II - Representative DES with Bioresorbable Polymers," on Tuesday, November 8 at 12:15 p.m. PST. Results will be presented by John Ormiston, M.D., Interventional Cardiologist with the Auckland Heart Group and Medical Director at Mercy Angiography in Auckland, New Zealand. William Wijns, M.D., Interventional Cardiologist with the Cardiovascular Center, Aalst, Belgium, and John Ormiston, M.D. are principal investigators for the study.

In the DESSOLVE I clinical trial, the MiStent DES was used to treat 30 patients with de novo lesions in coronary arteries ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm length stent. The study was performed in five centers in New Zealand, Australia and Belgium. This trial focused on evaluating the efficacy of the MiStent DES, and examined three independent groups of 10 patients using angiography, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) at four, six and eight months to evaluate the rate of in-stent late lumen loss (LLL) and the extent of tissue coverage of the stent at each time point.

Micell Technologies currently is conducting a second trial of the MiStent DES, DESSOLVE II; a prospective, single-blind, unbalanced randomized, controlled, multicenter superiority trial in Europe, Australia and New Zealand. This trial completed enrollment in July 2011 with 183 patients enrolled.

About the MiStent DES

The MiStent Sirolimus Eluting Coronary Stent System is designed to optimize healing in patients with coronary artery disease. Micell's rapid-absorbing drug/polymer formulation is intended to precisely and consistently control drug elution and polymer exposure duration to reduce the safety risks associated with current commercially available drug-eluting stent technologies.

Using an approved drug (sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a rigorously controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent DES leverages the benefits of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, which has demonstrated excellent deliverability, conformability and flexibility. GLP pre-clinical trials have shown that the drug/polymer coating is eliminated from the MiStent DES within 45 to 60 days. In addition, the polymer-based coating is fully absorbed in tissue by 90 days in vivo, at which point the bare-metal stent remains. The MiStent DES is being evaluated in international clinical studies and patient enrollment is complete in those studies.

The MiStent Sirolimus Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

About Micell Technologies Inc.

Micell Technologies® is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns associated with currently available drug-eluting stents. Micell also is developing a drug-coated balloon for vascular interventions. Visit us at

Micell, Micell Technologies, the Micell Logo, and MiStent are among the registered trademarks of Micell Technologies, Inc.

Contact: Micell Technologies
Arthur J. Benvenuto, Chairman & CEO
(919) 313-2104

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStentâ„¢ Drug-Eluting Coronary Stent (DES)
2. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
3. Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
6. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
7. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
8. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
9. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. Senesco Technologies Initiates Preclinical Studies for Cancer Target
Post Your Comments:
(Date:11/27/2015)... PHILADELPHIA , Nov. 27, 2015  Lannett ... that it has completed the acquisition of Kremers ... pharmaceuticals subsidiary of global biopharmaceuticals company UCB S.A. ... --> Lannett has acquired KU from UCB ... to certain adjustments, including a customary working capital ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... --> --> ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy can be efficiently combined with photodynamic therapy (PDT) ...
Breaking Medicine Technology:
(Date:11/28/2015)... PITTSBURGH, PA (PRWEB) , ... November 28, 2015 , ... ... Manalapan, N.J., has created the COUCH BUDDY. "I conceived of this design due to ... more comfort for couch users. It promotes relaxation and convenience, as well as increases ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... carried out by the University of Toronto and the University of British Columbia suggested ... hospitalizations for head injuries. The article explains that part of the reason for the ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the toilets were," said an inventor from Hillside, N.J. "Many people catch diseases ... cover so that individuals will always be protected from germs." , He developed ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... progress through sharing, the 2016 Building Better Radiology Marketing Programs meeting ... begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
Breaking Medicine News(10 mins):